Payment overview · 2025
General Payments
$1,943.05
115 reported records · 19 companies
Healthcare provider profile · identity verified
Emad Daher, MD
Allopathic & Osteopathic Physicians|Internal Medicine · PORT HURON, MI · NPI 1265415285
Verified facts
What the public records show
CMS Open Payments records show Emad Daher, MD received $1,943.05 in general payments during 2025 across 115 reported records.
Amgen Inc. accounted for 18.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 30 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Mounjaro, Nurtec Odt, Ozempic, Rybelsus, Trelegy Ellipta, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Ubrelvy by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 588 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 386 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 360 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 276 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 207 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 386 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Paxlovid by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $359.50 | 18.5% | 25 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $256.77 | 13.2% | 16 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $207.68 | 10.7% | 9 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $173.07 | 8.9% | 9 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $163.01 | 8.4% | 12 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $158.93 | 8.2% | 9 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $138.65 | 7.1% | 10 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $76.40 | 3.9% | 4 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $74.65 | 3.8% | 4 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $61.71 | 3.2% | 3 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $52.57 | 2.7% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $47.06 | 2.4% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $31.52 | 1.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $31.44 | 1.6% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $29.97 | 1.5% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $22.75 | 1.2% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $22.05 | 1.1% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $18.15 | 0.9% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $17.17 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,943.05 | 115 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $336.68 | 24 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $205.99 | 11 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $189.47 | 20 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $175.82 | 8 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $160.69 | 10 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $160.69 | 10 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $138.65 | 10 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $138.65 | 10 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $137.13 | 7 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $113.61 | 8 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $107.35 | 8 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $101.74 | 5 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $96.08 | 6 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $93.38 | 5 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $76.40 | 4 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $74.65 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $62.87 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $61.71 | 3 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $52.57 | 3 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $31.52 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $31.01 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $24.37 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $22.82 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $22.75 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $18.15 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $17.17 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.14 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.84 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $15.60 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $13.83 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 386 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 588 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 276 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 207 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 44 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 40 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
77 | 20 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
67 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
588 | 125 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
47 | 14 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
386 | 79 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
40 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
360 | 81 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
276 | 49 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
116 | 23 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
207 | 44 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
44 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
386 | 79 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
47 | 46 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
91 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2023 | 528 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1097 | 259 |
| Ezetimibe | Ezetimibe | 970 | 262 |
| Losartan Potassium | Losartan Potassium | 822 | 227 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 776 | 219 |
| Amlodipine Besylate | Amlodipine Besylate | 604 | 168 |
| Farxiga | Dapagliflozin Propanediol | 588 | 125 |
| Metoprolol Tartrate | Metoprolol Tartrate | 573 | 147 |
| Lisinopril | Lisinopril | 565 | 153 |
| Furosemide | Furosemide | 564 | 144 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 537 | 99 |
| Metoprolol Succinate | Metoprolol Succinate | 523 | 144 |
| Gabapentin | Gabapentin | 472 | 91 |
| Omeprazole | Omeprazole | 461 | 133 |
| Montelukast Sodium | Montelukast Sodium | 459 | 129 |
| Tamsulosin Hcl | Tamsulosin Hcl | 439 | 118 |
| Alprazolam | Alprazolam | 420 | 92 |
| Potassium Chloride | Potassium Chloride | 410 | 110 |
| Eliquis | Apixaban | 386 | 79 |
| Jardiance | Empagliflozin | 360 | 81 |
| Pantoprazole Sodium | Pantoprazole Sodium | 306 | 94 |
| Metformin Hcl | Metformin Hcl | 296 | 98 |
| Famotidine | Famotidine | 292 | 67 |
| Duloxetine Hcl | Duloxetine Hcl | 288 | 61 |
| Mounjaro | Tirzepatide | 276 | 49 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 269 | 69 |
| Clopidogrel | Clopidogrel Bisulfate | 263 | 62 |
| Allopurinol | Allopurinol | 257 | 70 |
| Escitalopram Oxalate | Escitalopram Oxalate | 257 | 56 |
| Sertraline Hcl | Sertraline Hcl | 256 | 62 |
| Trazodone Hcl | Trazodone Hcl | 232 | 45 |
| Spironolactone | Spironolactone | 213 | 49 |
| Ozempic | Semaglutide | 207 | 44 |
| Simvastatin | Simvastatin | 205 | 57 |
| Baclofen | Baclofen | 204 | 75 |
| Hydrochlorothiazide | Hydrochlorothiazide | 200 | 61 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 176 | 72 |
| Azithromycin | Azithromycin | 172 | 135 |
| Methylprednisolone | Methylprednisolone | 169 | 133 |
| Metformin Hcl Er | Metformin Hcl | 167 | 51 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 162 | 41 |
| Atenolol | Atenolol | 158 | 42 |
| Tramadol Hcl | Tramadol Hcl | 156 | 39 |
| Carvedilol | Carvedilol | 150 | 46 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 150 | 32 |
| Mirtazapine | Mirtazapine | 150 | 33 |
| Alendronate Sodium | Alendronate Sodium | 146 | 50 |
| Finasteride | Finasteride | 136 | 31 |
| Xarelto | Rivaroxaban | 130 | 29 |
| Pravastatin Sodium | Pravastatin Sodium | 129 | 34 |
| Clonazepam | Clonazepam | 128 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 123 | 41 |
| Zolpidem Tartrate | Zolpidem Tartrate | 122 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 121 | 30 |
| Glimepiride | Glimepiride | 121 | 35 |
| Trulicity | Dulaglutide | 116 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 115 | 28 |
| Cefuroxime | Cefuroxime Axetil | 109 | 77 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 100 | 75 |
| Lorazepam | Lorazepam | 100 | 26 |
| Memantine Hcl | Memantine Hcl | 100 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 100 | 20 |
| Pioglitazone Hcl | Pioglitazone Hcl | 99 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 96 | 46 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 93 | 18 |
| Pregabalin | Pregabalin | 92 | 23 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 91 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 88 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 88 | 22 |
| Donepezil Hcl | Donepezil Hcl | 85 | 17 |
| Lansoprazole | Lansoprazole | 82 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 82 | 20 |
| Lamotrigine | Lamotrigine | 77 | suppressed |
| Synthroid | Levothyroxine Sodium | 77 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 76 | 25 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 72 | 15 |
| Januvia | Sitagliptin Phosphate | 72 | 18 |
| Torsemide | Torsemide | 71 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 70 | 38 |
| Myrbetriq | Mirabegron | 67 | 17 |
| Amiodarone Hcl | Amiodarone Hcl | 65 | 20 |
| Ondansetron Hcl | Ondansetron Hcl | 64 | 25 |
| Buspirone Hcl | Buspirone Hcl | 63 | 15 |
| Levetiracetam | Levetiracetam | 63 | 12 |
| Lovastatin | Lovastatin | 60 | suppressed |
| Repatha Sureclick | Evolocumab | 60 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 59 | 16 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 57 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 57 | 46 |
| Aripiprazole | Aripiprazole | 56 | 15 |
| Clonidine Hcl | Clonidine Hcl | 56 | 13 |
| Nystatin | Nystatin | 56 | 27 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 55 | 16 |
| Fluconazole | Fluconazole | 54 | 36 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 53 | 15 |
| Celecoxib | Celecoxib | 52 | 15 |
| Methocarbamol | Methocarbamol | 52 | 15 |
| Novolog | Insulin Aspart | 50 | 14 |
| Prednisone | Prednisone | 50 | 24 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 49 | 30 |
| Diclofenac Sodium | Diclofenac Sodium | 47 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 47 | 20 |
| Paxlovid | Nirmatrelvir/Ritonavir | 47 | 46 |
| Symbicort | Budesonide/Formoterol Fumarate | 47 | 14 |
| Glipizide Er | Glipizide | 46 | suppressed |
| Sucralfate | Sucralfate | 46 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 46 | 11 |
| Novolog Flexpen | Insulin Aspart | 45 | 16 |
| Raloxifene Hcl | Raloxifene Hcl | 45 | 12 |
| Warfarin Sodium | Warfarin Sodium | 45 | 12 |
| Enalapril Maleate | Enalapril Maleate | 44 | 12 |
| Meclizine Hcl | Meclizine Hcl | 44 | 31 |
| Rybelsus | Semaglutide | 44 | 11 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 43 | 11 |
| Diazepam | Diazepam | 42 | 18 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 42 | suppressed |
| Enulose | Lactulose | 41 | suppressed |
| Ramipril | Ramipril | 41 | 11 |
| Valsartan | Valsartan | 41 | 12 |
| Fenofibrate | Fenofibrate | 40 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 40 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 40 | 15 |
| Hydrocortisone | Hydrocortisone | 39 | 12 |
| Primidone | Primidone | 39 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 38 | 25 |
| Midodrine Hcl | Midodrine Hcl | 38 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 38 | suppressed |
| Nitroglycerin | Nitroglycerin | 37 | 28 |
| Ventolin Hfa | Albuterol Sulfate | 37 | 13 |
| Humalog | Insulin Lispro | 36 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 36 | 15 |
| Lactulose | Lactulose | 35 | 14 |
| Cephalexin | Cephalexin | 34 | 31 |
| Cholestyramine | Cholestyramine (With Sugar) | 34 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 34 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 33 | suppressed |
| Ibuprofen | Ibuprofen | 33 | 11 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 33 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 33 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 33 | 24 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 32 | 12 |
| Bupropion Xl | Bupropion Hcl | 32 | 13 |
| Meloxicam | Meloxicam | 32 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 32 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 31 | suppressed |
| Colchicine | Colchicine | 30 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 24 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 30 | 12 |
| Repatha Syringe | Evolocumab | 30 | suppressed |
| Ssd | Silver Sulfadiazine | 30 | suppressed |
| Vascepa | Icosapent Ethyl | 30 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 29 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 29 | 19 |
| Benazepril Hcl | Benazepril Hcl | 28 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 28 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 28 | suppressed |
| Levemir | Insulin Detemir | 28 | suppressed |
| Levemir Flexpen | Insulin Detemir | 28 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 28 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 28 | 12 |
| Amoxicillin | Amoxicillin | 27 | 21 |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 27 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Febuxostat | Febuxostat | 26 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | suppressed |
| Levofloxacin | Levofloxacin | 26 | 18 |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 24 | suppressed |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 24 | suppressed |
| Metronidazole | Metronidazole | 24 | 18 |
| Ranolazine Er | Ranolazine | 24 | suppressed |
| Fycompa | Perampanel | 23 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 23 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Belsomra | Suvorexant | 22 | suppressed |
| Dexamethasone | Dexamethasone | 22 | 19 |
| Flecainide Acetate | Flecainide Acetate | 22 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 22 | suppressed |
| Ubrelvy | Ubrogepant | 22 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 21 | suppressed |
| Mirabegron Er | Mirabegron | 21 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 21 | 18 |
| Risperidone | Risperidone | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | 12 |
| Nurtec Odt | Rimegepant Sulfate | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Bumetanide | Bumetanide | 19 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Olanzapine | Olanzapine | 19 | suppressed |
| Restasis | Cyclosporine | 19 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 18 | suppressed |
| Budesonide | Budesonide | 18 | suppressed |
| Calcium Acetate | Calcium Acetate | 18 | suppressed |
| Klor-Con M20 | Potassium Chloride | 18 | suppressed |
| Temazepam | Temazepam | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 17 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 17 | suppressed |
| Nadolol | Nadolol | 17 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 17 | suppressed |
| Praluent Pen | Alirocumab | 17 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 16 | suppressed |
| Nystop | Nystatin | 16 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 16 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 16 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Insulin Lispro | Insulin Lispro | 15 | suppressed |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 15 | suppressed |
| Repaglinide | Repaglinide | 15 | suppressed |
| Tradjenta | Linagliptin | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Fentanyl | Fentanyl | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Brilinta | Ticagrelor | 13 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 13 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 13 | suppressed |
| Lumigan | Bimatoprost | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 11 |
| Tadalafil | Tadalafil | 13 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Saxagliptin Hcl | Saxagliptin Hcl | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Emgality Syringe | Galcanezumab-Gnlm | 11 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 11 | suppressed |
| Jantoven | Warfarin Sodium | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Moxifloxacin Hcl | Moxifloxacin Hcl | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 11 | suppressed |
| Perindopril Erbumine | Perindopril Erbumine | 11 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 11 | 11 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,943.05 · 115 records | Amgen Inc. | AIRSUPRA, BREZTRI, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FARXIGA, GEMTESA, KISUNLA, LEQVIO, MOUNJARO, NUPLAZID, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, TZIELD, The Cologuard Plus Collection Kit, UBRELVY, Veozah, WATCHMAN FLX, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 20 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error